// App-Quantinova.ai

421 : Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

Researchers

Presenter

  • Francesca Aroldi

Principal Investigators

  • Joseph Sacco

  • Kevin Harrington

  • Anna Olsson-Brown

  • Pablo Nanclares

  • Lavita Menezes

  • Praveen Bommareddy

  • Suzanne Thomas

  • Howard Kaufman

  • Selda Samakoglu

  • Robert Coffin

  • Mark Middleton

Medical Centers

  • OCDEM, University of Oxford, Oxford, UK

  • University of Liverpool, Liverpool, UK

  • The Institute of Cancer Research, London, UK

  • Replimune, Inc., Woburn, MA

  • Massachusetts General Hospital, Boston, MA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved